Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILK-GDM-CIR-0602K
PACTR202609626966418Phase 2Not yet recruiting
- Sponsor
- Infectious Diseases Institute.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azemiglitazone in gestational diabetes mellitus (GDM) (2 arms), sponsored by Infectious Diseases Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
azemiglitazone
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on PACTR202609626966418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609626966418.